# Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma

> **NCT06594211** · NA · NOT_YET_RECRUITING · sponsor: **RenJi Hospital** · enrollment: 18 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** ACT-001 CAR-NK cell

## Key facts

- **NCT ID:** NCT06594211
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-09
- **Primary completion:** 2028-10-09
- **Final completion:** 2028-10-09
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06594211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06594211, "Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT06594211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*